<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="668">
  <stage>Registered</stage>
  <submitdate>30/08/2005</submitdate>
  <approvaldate>30/08/2005</approvaldate>
  <nctid>NCT00141375</nctid>
  <trial_identification>
    <studytitle>To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.</studytitle>
    <scientifictitle>An Open-Label Extension to Evaluate the Safety and Efficacy of Pregabalin for Treatment of Chronic Central Neuropathic Pain After Spinal Cord Injury.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>1008-000-202</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neuropathic Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Pregabalin

Treatment: drugs: Pregabalin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and Efficacy</outcome>
      <timepoint />
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must have met the inclusion criteria of the preceding double-blind BID study in
             central pain following spinal cord injury.

          -  Must have received study medication under double-blind conditions.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients cannot participate if they experienced a serious adverse event during the
             previous double-blind BID study which was determined to be related to the study
             medication.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Pfizer Investigational Site - Little Bay</hospital>
    <hospital>Pfizer Investigational Site - St. Leonards</hospital>
    <hospital>Pfizer Investigational Site - Warrawong</hospital>
    <hospital>Pfizer Investigational Site - Woolloongabba</hospital>
    <hospital>Pfizer Investigational Site - Heidelberg</hospital>
    <hospital>Pfizer Investigational Site - Shenton Park</hospital>
    <hospital>Pfizer Investigational Site - NSW</hospital>
    <postcode>2036 - Little Bay</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2502 - Warrawong</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>6008 - Shenton Park</postcode>
    <postcode> - NSW</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain
      after spinal cord injury.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00141375</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>